Eagle Pharmaceuticals, Inc. – NASDAQ:EGRX

Add to watchlist

$3.18

+2.68

+536%

Market open

Closed in about 4 hours

-91.69%

month

-91.69%

quarter

-90.37%

year

Market Cap	7.12M
Enterprise value	415.45M

P/E	10.67
EV/Sales	1.31
EV/EBITDA	5.74
Price/Sales	1.28
Price/Book	1.74
PEG ratio	0.02
EPS	1.19

Revenue	257.55M
EBITDA	39.32M
Income	15.56M
Revenue Q/Q	-12.80%
Revenue Y/Y	-5.37%

Profit margin	11.26%
Oper. margin	25.57%
Gross margin	70.01%
EBIT margin	25.57%
EBITDA margin	15.27%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Profit margin
Sep 2022	65.90M	-3.51M	-5.33%
Dec 2022	60.69M	8.16M	13.45%
Mar 2023	66.30M	5.75M	8.67%
Jun 2023	64.64M	5.16M	7.99%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Debt to assets
Sep 2022	390067000	154.66M	39.65%
Dec 2022	406160000	172.6M	42.5%
Mar 2023	414175000	171.33M	41.37%
Jun 2023	404822000	152.78M	37.74%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Cash Flow
Sep 2022	-13.23M	-11.23M	3.29M
Dec 2022	37.55M	-9K	2.38M
Mar 2023	-33.51M	-12.55M	12.64M
Jun 2023	-126K	-6K	-6.41M

Eagle Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Eagle Pharmaceuticals
Employees

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Employee count
Aug 2023	134
Sep 2023	134
Oct 2023	134
Nov 2023	134
Dec 2023	134
Jan 2024	134
Feb 2024	134
Mar 2024	134
Apr 2024	134
May 2024	134
Jun 2024	134
Jul 2024	134

Eagle Pharmaceuticals
Hedge Funds Holdings Q3 2022

78.54% -11.40%

of EGRX is owned by hedge funds

133 -27

hedge funds hold EGRX stock

10.08M -1.52M

shares is hold by hedge funds

EGRX hedge funds holdings changes

Eagle Pharmaceuticals
Insider Trading

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Insider trades (number of shares)
Period	Buy	Sel
May 2023	0	60000
Oct 2023	0	20245
Nov 2023	0	21619

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Nov 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	10,694	$13.87	$148,326
Sale	1 Nov 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	10,925	$13.82	$150,984
Option	27 Oct 2023	GRAVES MICHAEL director director	Common Stock	9,360	$4.94	$46,238
Option	27 Oct 2023	GRAVES MICHAEL director director	Stock Option (right to buy)	9,360	$4.94	$46,238
Sale	3 Oct 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	710	$15.11	$10,728
Sale	3 Oct 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	10,024	$14.41	$144,446
Sale	2 Oct 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	9,511	$15.23	$144,853
Sale	16 May 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	15,000	$19.98	$299,700
Sale	15 May 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	14,800	$21.06	$311,688
Sale	15 May 2023	TARRIFF SCOTT director, 10 perc..	Common Stock	200	$21.52	$4,304

EGRX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application FORMULATIONS OF BENDAMUSTINE Filling date: 10 May 2022 Issue date: 25 Aug 2022	10 May 2022	25 Aug 2022
Application	Application METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE Filling date: 2 Dec 2021 Issue date: 24 Mar 2022	2 Dec 2021	24 Mar 2022
Application	Application FULVESTRANT FORMULATIONS Filling date: 18 Nov 2021 Issue date: 10 Mar 2022	18 Nov 2021	10 Mar 2022
Application	Application FORMULATIONS OF BENDAMUSTINE Filling date: 26 Aug 2021 Issue date: 23 Dec 2021	26 Aug 2021	23 Dec 2021
Grant	Grant Utility: Fulvestrant formulations Filling date: 8 Apr 2013 Issue date: 23 Nov 2021	8 Apr 2013	23 Nov 2021
Application	Application FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE Filling date: 19 Jul 2021 Issue date: 11 Nov 2021	19 Jul 2021	11 Nov 2021
Grant	Grant Utility: Formulations of bendamustine Filling date: 12 Jul 2019 Issue date: 31 Aug 2021	12 Jul 2019	31 Aug 2021
Application	Application FULVESTRANT FORMULATIONS Filling date: 16 Sep 2020 Issue date: 26 Aug 2021	16 Sep 2020	26 Aug 2021
Application	Application DANTROLENE FORMULATIONS AND METHODS OF THEIR USE Filling date: 21 May 2019 Issue date: 5 Aug 2021	21 May 2019	5 Aug 2021
Application	Application FORMULATIONS OF BENDAMUSTINE Filling date: 8 May 2020 Issue date: 15 Apr 2021	8 May 2020	15 Apr 2021

Eagle Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 9 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 13 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 7 Nov 2022	Q3 2022 Earnings Call Transcript

EGRX earnings call transcripts

Eagle Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Scott L. Tarriff (1960) Founder, Pres, Chief Executive Officer & Director	65	$1,400,000
Mr. David M. Pernock (1953) Executive Vice President of Operations	72	$896,320
Mr. Brian Joseph Cahill (1969) Chief Financial Officer	56	$500,240

Eagle Pharmaceuticals
Latest News

Friday, 15 November 2024
17:00	Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration	globenewswire.com
Tuesday, 22 October 2024
19:30	INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders	accesswire.com
Tuesday, 8 October 2024
14:02	Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares	gurufocus.com
Tuesday, 27 August 2024
16:30	Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	globenewswire.com
Wednesday, 22 May 2024
09:00	Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	globenewswire.com
Monday, 15 April 2024
07:00	Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida	globenewswire.com
Friday, 12 April 2024
16:05	Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K	globenewswire.com
Friday, 9 February 2024
12:15	Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX	accesswire.com
12:00	EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options	prnewswire.com
11:30	Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX	accesswire.com
07:30	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX	accesswire.com
05:45	Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX	prnewswire.com
05:20	Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX	accesswire.com
05:00	FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm	accesswire.com
Thursday, 8 February 2024
18:30	Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More	accesswire.com
16:30	Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky	accesswire.com
16:15	EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit	prnewswire.com
15:20	Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline	accesswire.com
15:00	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)	businesswire.com
05:45	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024	prnewswire.com
04:00	FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm	accesswire.com
Wednesday, 7 February 2024
15:20	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX	prnewswire.com
Tuesday, 6 February 2024
14:15	EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit	prnewswire.com
05:45	SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline	prnewswire.com
04:00	FEBRUARY 9 DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm	accesswire.com
Saturday, 3 February 2024
10:30	ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX	prnewswire.com
07:00	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm	accesswire.com
Friday, 2 February 2024
09:45	EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options	prnewswire.com
08:00	SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm	accesswire.com
05:45	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)	prnewswire.com

Ideas & Opinions

Seeking Alpha 7 Mar 2022

Endo: About As Bad As It Gets
Seeking Alpha 16 Dec 2021

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Seeking Alpha 2 Nov 2021

Endo: A Win In California But Equity Value Still A Question
Seeking Alpha 31 Aug 2021

Endo International: Loses Vasostrict Trial
Seeking Alpha 20 Aug 2021

Endo International: Hires Restructuring Advisor
Seeking Alpha 7 Aug 2021

Endo International: All About Ongoing Litigation
Seeking Alpha 16 Jun 2021

Eagle Pharmaceuticals: A Potential Reopening Play

Frequently Asked Questions (FAQ)

What's the price of Eagle Pharmaceuticals stock today?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $3.18.
When is Eagle Pharmaceuticals's next earnings date?

Unfortunately, Eagle Pharmaceuticals's (EGRX) next earnings date is currently unknown.
Does Eagle Pharmaceuticals pay dividends?

No, Eagle Pharmaceuticals does not pay dividends.
How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of 7.12M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 84.56% to 316.61M US dollars.
What is Eagle Pharmaceuticals's stock symbol?

Eagle Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EGRX".
What is Eagle Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Eagle Pharmaceuticals?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Eagle Pharmaceuticals's key executives?
Eagle Pharmaceuticals's management team includes the following people:
- Mr. Scott L. Tarriff Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,400,000)
- Mr. David M. Pernock Executive Vice President of Operations(age: 72, pay: $896,320)
- Mr. Brian Joseph Cahill Chief Financial Officer(age: 56, pay: $500,240)
Is Eagle Pharmaceuticals founder-led company?

Yes, Eagle Pharmaceuticals is a company led by its founder Mr. Scott L. Tarriff.
How many employees does Eagle Pharmaceuticals have?

As Jul 2024, Eagle Pharmaceuticals employs 134 workers.
When Eagle Pharmaceuticals went public?

Eagle Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 12 Feb 2014.
What is Eagle Pharmaceuticals's official website?

The official website for Eagle Pharmaceuticals is eagleus.com.
Where are Eagle Pharmaceuticals's headquarters?

Eagle Pharmaceuticals is headquartered at 50 Tice Boulevard, Woodcliff Lake, NJ.
How can i contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals's mailing address is 50 Tice Boulevard, Woodcliff Lake, NJ and company can be reached via phone at +20 13 265300.

Eagle Pharmaceuticals, Inc.

eagleus.com

Exchange:

NASDAQ

Full time employees:

134

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

+20 13 265300

50 Tice Boulevard
Woodcliff Lake, NJ 07677

CIK: 0000827871
ISIN: US2697961082
CUSIP: 269796108